Literature DB >> 18379015

Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy.

Nabil Kabbara, Claire Lacroix, Regis Peffault de Latour, Gérard Socié, Mahmoud Ghannoum, Patricia Ribaud.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18379015     DOI： 10.3324/haematol.11149

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  19 in total

1.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

2.  Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.

Authors:  Jeffrey M Rybak; C Michael Dickens; Josie E Parker; Kelly E Caudle; Kayihura Manigaba; Sarah G Whaley; Andrew T Nishimoto; Arturo Luna-Tapia; Sujoy Roy; Qing Zhang; Katherine S Barker; Glen E Palmer; Thomas R Sutter; Ramin Homayouni; Nathan P Wiederhold; Steven L Kelly; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France.

Authors:  Elodie Blanchard; Olivier Lortholary; Karine Boukris-Sitbon; Marie Desnos-Ollivier; Françoise Dromer; Didier Guillemot
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

Review 4.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

5.  Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.

Authors:  Keunsook K Lee; Donna M Maccallum; Mette D Jacobsen; Louise A Walker; Frank C Odds; Neil A R Gow; Carol A Munro
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

Review 6.  Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Authors:  Danièle Maubon; Cécile Garnaud; Thierry Calandra; Dominique Sanglard; Muriel Cornet
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

7.  In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Authors:  D Andes; D J Diekema; M A Pfaller; J Bohrmuller; K Marchillo; A Lepak
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

8.  Candida guilliermondii Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia.

Authors:  Laura Judith Marcos-Zambrano; Mireia Puig-Asensio; Felipe Pérez-García; Pilar Escribano; Carlos Sánchez-Carrillo; Oscar Zaragoza; Belén Padilla; Manuel Cuenca-Estrella; Benito Almirante; M Teresa Martín-Gómez; Patricia Muñoz; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

9.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Authors:  D J Diekema; S A Messer; L B Boyken; R J Hollis; J Kroeger; S Tendolkar; M A Pfaller
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

10.  Fungal echinocandin resistance.

Authors:  Louise A Walker; Neil A R Gow; Carol A Munro
Journal:  Fungal Genet Biol       Date:  2009-09-19       Impact factor: 3.495
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.